TABLE 2.
Univariate and multivariate analyses of RFS and OS with IGKC expression and clinicopathological characteristics in ESCC patients with/without chemotherapy
| nNACT | NACT | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||||
| HR | 95% CI | p Value a | HR (95% CI) | 95% CI | p Value a | HR (95% CI) | 95% CI | p Value a | HR (95% CI) | 95% CI | p Value a | |||
| RFS | ||||||||||||||
| Sex | ||||||||||||||
| Female | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| Male | 0.86 | 0.19‐3.8 | .84 | 0.50 | 0.095‐2.6 | .40 | 1.4 | 0.54‐3.5 | .51 | 1.5 | 0.58‐3.9 | .40 | ||
| Age | ||||||||||||||
| <65 b | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| ≥65 | 1.3 | 0.45‐3.8 | .62 | 1.2 | 0.37‐3.9 | .76 | 1.1 | 0.60‐2.0 | .77 | 1.2 | 0.64‐2.2 | .60 | ||
| T stage c | ||||||||||||||
| T1, 2 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| T3, 4 | 11.3 | 3.7‐35 | <.0001 | 17.7 | 3.5‐88.2 | .0005 | 1.0 | 0.55‐1.8 | .99 | 1.1 | 0.59‐2.0 | .79 | ||
| Lymph node metastasis | ||||||||||||||
| Negative | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| Positive | 3.6 | 1.3‐10 | .017 | 2.2 | 0.66‐7.2 | .20 | 1.3 | 0.59‐3.0 | .49 | 1.3 | 0.59‐3.1 | .79 | ||
| IGKC expression | ||||||||||||||
| Low | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| High | 0.063 | 0.083‐0.48 | .0078 | 0.043 | 0.0050‐0.37 | .0040 | 0.38 | 0.19‐0.75 | .0054 | 0.35 | 0.18‐0.71 | .0037 | ||
| OS | ||||||||||||||
| Sex | ||||||||||||||
| Female | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| Male | 0.58 | 0.12‐2.7 | .48 | 0.23 | 0.033‐1.6 | .14 | 1.7 | 0.39‐7.1 | .49 | 1.6 | 0.37‐7.1 | .52 | ||
| Age | ||||||||||||||
| <65 b | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| ≥65 | 1.1 | 0.34‐3.7 | .85 | 1.2 | 0.31‐4.4 | .82 | 1.4 | 0.62‐3.1 | .44 | 1.7 | 0.73‐3.9 | .22 | ||
| T stage c | ||||||||||||||
| T1, 2 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| T3, 4 | 10.7 | 3.1‐37.3 | .0002 | 17.8 | 3.4‐94.1 | .0007 | 1.2 | 0.55‐2.7 | .62 | 1.5 | 0.63‐3.4 | .38 | ||
| Lymph node metastasis | ||||||||||||||
| Negative | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| Positive | 3.6 | 1.1‐12.0 | .033 | 2.3 | 0.52‐9.8 | .27 | 1.6 | 0.46‐5.2 | .48 | 1.6 | 0.47‐5.4 | .45 | ||
| IGKC expression | ||||||||||||||
| Low | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
| High | 0.072 | 0.0092‐0.56 | .012 | 0.046 | 0.0052‐0.41 | .0059 | 0.38 | 0.15‐0.95 | .039 | 0.33 | 0.13‐0.84 | .021 | ||
a
Cox regression analysis.
b
Mean age.
c
According to the Union for International Cancer Control (UICC) staging system.
RFS, recurrence‐free survival; OS, overall survival; nNACT, treated without neoadjuvant chemotherapy; NACT, treated with neoadjuvant chemotherapy; HR, hazard ratio; CI, confidence interval; IGKC, immunoglobulin κ C.
Bold; Significant p values.